About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there ...

The day’s sell trades were not limited to Palantir, as ARK also reduced its position in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) by selling 95,502 shares worth $1,073,442. ARK’s trading ...

Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $45.00. The company has a 50 day moving average of $12.04 and a two-hundred day moving average of $15.61.

The market expects Arcturus Therapeutics (ARCT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be ...

Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...